These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1200 related items for PubMed ID: 28650134

  • 1. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP, Abate ML, Gaia S, Petrini E, Bosco C, Olivero A, Rosso C, Ciancio A, Pellicano R, Saracco GM, Rizzetto M, Smedile A.
    Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
    Seo SI, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, Jang MK, Lee JH, Kim JS, Kim HY, Kim DJ, Lee MS, Park CK.
    World J Gastroenterol; 2015 Apr 07; 21(13):3928-35. PubMed ID: 25852278
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J, Xiang Z, Bai L, He L, Tan L, Hu M, Ren Y.
    Cancer Biomark; 2018 Apr 07; 23(2):235-242. PubMed ID: 30103302
    [Abstract] [Full Text] [Related]

  • 4. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS, Kim DY, Han KH, Kim HS, Shin SH, Jung KS, Kim BK, Kim SU, Park JY, Ahn SH.
    Scand J Gastroenterol; 2016 Mar 07; 51(3):344-53. PubMed ID: 26340708
    [Abstract] [Full Text] [Related]

  • 5. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
    Ricco G, Cosma C, Bedogni G, Biasiolo A, Guarino M, Pontisso P, Morisco F, Oliveri F, Cavallone D, Bonino F, Plebani M, Brunetto MR.
    Cancer Biomark; 2020 Mar 07; 29(2):189-196. PubMed ID: 32623383
    [Abstract] [Full Text] [Related]

  • 6. Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma.
    Wang Q, Chen Q, Zhang X, Lu XL, Du Q, Zhu T, Zhang GY, Wang DS, Fan QM.
    World J Gastroenterol; 2019 Sep 28; 25(36):5515-5529. PubMed ID: 31576097
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma.
    Wang G, Lu X, Du Q, Zhang G, Wang D, Wang Q, Guo X.
    Sci Rep; 2020 Aug 11; 10(1):13519. PubMed ID: 32782270
    [Abstract] [Full Text] [Related]

  • 8. A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B.
    Yang T, Xing H, Wang G, Wang N, Liu M, Yan C, Li H, Wei L, Li S, Fan Z, Shi M, Chen W, Cai S, Pawlik TM, Soh A, Beshiri A, Lau WY, Wu M, Zheng Y, Shen F.
    Clin Chem; 2019 Dec 11; 65(12):1543-1553. PubMed ID: 31672853
    [Abstract] [Full Text] [Related]

  • 9. Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.
    Abdel-Razik A, Elhelaly R, Elzehery R, El-Diasty A, Abed S, Elhammady D, Tawfik A.
    Eur J Gastroenterol Hepatol; 2016 May 11; 28(5):599-605. PubMed ID: 26741637
    [Abstract] [Full Text] [Related]

  • 10. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
    Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, Oh EJ.
    World J Gastroenterol; 2013 Jan 21; 19(3):339-46. PubMed ID: 23372355
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
    Huang S, Jiang F, Wang Y, Yu Y, Ren S, Wang X, Yin P, Lou J.
    Tumour Biol; 2017 Jun 21; 39(6):1010428317705763. PubMed ID: 28621228
    [Abstract] [Full Text] [Related]

  • 12. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Yoon YJ, Han KH, Kim DY.
    Scand J Gastroenterol; 2009 Jun 21; 44(7):861-6. PubMed ID: 19391065
    [Abstract] [Full Text] [Related]

  • 13. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H, Li B, Li Z, Wei Q, Ren L.
    BMC Cancer; 2021 Apr 13; 21(1):401. PubMed ID: 33849479
    [Abstract] [Full Text] [Related]

  • 14. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS, Park JW, Jang JS, Kim HJ, Shin WG, Kim KH, Lee JH, Kim HY, Jang MK.
    J Clin Gastroenterol; 2009 Apr 13; 43(5):482-8. PubMed ID: 19197197
    [Abstract] [Full Text] [Related]

  • 15. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.
    Park SJ, Jang JY, Jeong SW, Cho YK, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Park S, Bang HI.
    Medicine (Baltimore); 2017 Mar 13; 96(11):e5811. PubMed ID: 28296720
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
    Ismail MM, Morsi HK, Abdulateef NA, Noaman MK, Abou El-Ella GA.
    Scand J Clin Lab Invest; 2017 May 13; 77(3):175-183. PubMed ID: 28276727
    [Abstract] [Full Text] [Related]

  • 17. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R, Wang B, Ding H, Shen H, Li Y, Chen X.
    Chin Med J (Engl); 2002 Jan 13; 115(1):42-5. PubMed ID: 11930656
    [Abstract] [Full Text] [Related]

  • 18. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
    Poté N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, Puy H, Bedossa P, Paradis V.
    J Hepatol; 2015 Apr 13; 62(4):848-54. PubMed ID: 25450201
    [Abstract] [Full Text] [Related]

  • 19. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
    Caviglia GP, Ribaldone DG, Abate ML, Ciancio A, Pellicano R, Smedile A, Saracco GM.
    Scand J Gastroenterol; 2018 Jun 13; 53(6):734-740. PubMed ID: 29667463
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of Serum GDF15, AFP, and PIVKA-II as Diagnostic Markers for HBV-Associated Hepatocellular Carcinoma.
    Chen J, Tang D, Xu C, Niu Z, Li H, Li Y, Zhang P.
    Lab Med; 2021 Jul 01; 52(4):381-389. PubMed ID: 33159511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.